2022 |
07/29 | 13:30 2022年12月期第2四半期決算短信〔IFRS〕(連結) |
07/26 | 16:00 Paradise超音波腎デナベーションシステム高血圧患者対象のRADIANCE-II米国ピボタル試験にて主要評価項目を達成 |
07/26 | 16:00 業績予想の修正に関するお知らせ |
07/26 | 4,942 | 4,958 | 4,876 | 4,887 | -1.39% | 792,900 | 2兆7261億 | +0.97% |
07/25 | 4,955 | 4,990 | 4,923 | 4,956 | +0.08% | 665,100 | 2兆7646億 | +2.8% |
07/22 | 4,976 | 4,983 | 4,900 | 4,952 | -0.52% | 797,300 | 2兆7624億 | +3.23% |
07/21 | 4,902 | 4,987 | 4,899 | 4,978 | +0.79% | 840,900 | 2兆7769億 | +4.27% |
07/20 | 4,906 | 4,949 | 4,879 | 4,939 | +1.56% | 955,300 | 2兆7551億 | +4.04% |
07/19 | 4,902 | 4,914 | 4,838 | 4,863 | -1.1% | 645,500 | 2兆7127億 | +2.92% |
07/15 | 4,941 | 4,966 | 4,898 | 4,917 | -0.43% | 866,000 | 2兆7428億 | +4.42% |
07/14 | 4,910 | 4,960 | 4,875 | 4,938 | +0.2% | 915,300 | 2兆7545億 | +5.31% |
07/13 | 4,937 | 4,976 | 4,915 | 4,928 | -0.36% | 809,400 | 2兆7490億 | +5.52% |
07/12 | 4,954 | 4,985 | 4,924 | 4,946 | -0.76% | 1,058,400 | 2兆7590億 | +6.37% |
07/11 | 4,949 | 5,000 | 4,920 | 4,984 | +2.15% | 1,163,900 | 2兆7802億 | +7.72% |
07/08 | 4,950 | 4,962 | 4,832 | 4,879 | -2.42% | 1,593,500 | 2兆7216億 | +6.02% |
07/07 | 4,972 | 5,000 | 4,923 | 5,000 | +1.32% | 1,391,000 | 2兆7891億 | +9.15% |
07/06 | 4,867 | 4,964 | 4,860 | 4,935 | +0.8% | 1,508,200 | 2兆7529億 | +8.39% |
07/05 | 4,881 | 4,896 | 4,830 | 4,896 | +0.29% | 1,055,000 | 2兆7311億 | +8.06% |
07/04 | 4,900 | 4,929 | 4,840 | 4,882 | +2.37% | 1,104,400 | 2兆7233億 | +8.32% |
07/01 | 4,858 | 4,904 | 4,753 | 4,769 | -1.02% | 1,080,500 | 2兆6603億 | +6.28% |
06/30 | 4,815 | 4,861 | 4,811 | 4,818 | +0.27% | 1,439,500 | 2兆6876億 | +7.81% |
06/29 | 4,850 | 4,878 | 4,793 | 4,805 | -2.63% | 1,703,800 | 2兆6804億 | +7.95% |
06/28 | 4,809 | 4,950 | 4,797 | 4,935 | +2.88% | 1,611,700 | 2兆7529億 | +11.27% |
06/27 | 4,567 | 4,805 | 4,518 | 4,797 | +5.38% | 2,104,900 | 2兆6759億 | +8.6% |
06/27 | 9:00 抗精神病薬「ブレクスピプラゾール」アルツハイマー型認知症に伴う行動障害を対象としたグローバルフェーズ3試験で主要評価項目を達成し有効性を確認 |
06/24 | 4,560 | 4,565 | 4,499 | 4,552 | +0.6% | 702,600 | 2兆5392億 | +3.34% |
06/23 | 4,490 | 4,554 | 4,490 | 4,525 | +0.67% | 754,300 | 2兆5242億 | +2.82% |
06/22 | 4,465 | 4,517 | 4,453 | 4,495 | +1.33% | 735,100 | 2兆5074億 | +2.18% |
06/21 | 4,430 | 4,462 | 4,379 | 4,436 | +0.66% | 904,200 | 2兆4745億 | +0.8% |
06/20 | 4,413 | 4,447 | 4,380 | 4,407 | +1.08% | 552,200 | 2兆4583億 | +0.11% |
06/17 | 17:30 アリピプラゾール2ヵ月持続性注射剤統合失調症の適応で欧州医薬品庁が申請受理 |
06/17 | 4,322 | 4,388 | 4,307 | 4,360 | 0% | 1,339,700 | 2兆4321億 | -0.95% |
06/16 | 4,378 | 4,415 | 4,358 | 4,360 | +1.14% | 704,000 | 2兆4321億 | -0.91% |
06/15 | 4,394 | 4,395 | 4,306 | 4,311 | -1.64% | 764,400 | 2兆4048億 | -2.07% |
06/14 | 4,406 | 4,426 | 4,366 | 4,383 | -1.66% | 862,500 | 2兆4449億 | -0.52% |
06/13 | 4,381 | 4,464 | 4,381 | 4,457 | +0.47% | 835,800 | 2兆4862億 | +1.09% |
06/10 | 4,474 | 4,474 | 4,424 | 4,436 | -0.65% | 1,085,100 | 2兆4745億 | +0.64% |
06/09 | 4,450 | 4,492 | 4,431 | 4,465 | +0.81% | 865,800 | 2兆4907億 | +1.22% |
06/08 | 4,396 | 4,433 | 4,365 | 4,429 | +1.72% | 796,600 | 2兆4706億 | +0.43% |
06/07 | 4,330 | 4,379 | 4,320 | 4,354 | -0.25% | 801,400 | 2兆4288億 | -1.2% |
06/06 | 4,320 | 4,376 | 4,316 | 4,365 | +0.55% | 732,600 | 2兆4349億 | -0.82% |
06/03 | 4,342 | 4,368 | 4,321 | 4,341 | +0.56% | 771,000 | 2兆4215億 | -1.27% |
06/02 | 4,375 | 4,383 | 4,304 | 4,317 | -1.48% | 954,300 | 2兆4081億 | -1.73% |
06/01 | 4,340 | 4,432 | 4,324 | 4,382 | +2.17% | 1,198,600 | 2兆4444億 | -0.18% |
05/31 | 4,391 | 4,422 | 4,289 | 4,289 | -2.01% | 5,562,700 | 2兆3925億 | -2.19% |
05/30 | 4,349 | 4,410 | 4,330 | 4,377 | +1.06% | 1,250,000 | 2兆4416億 | -0.07% |
05/27 | 4,400 | 4,409 | 4,313 | 4,331 | -0.57% | 889,400 | 2兆4159億 | -0.89% |
05/26 | 4,409 | 4,441 | 4,354 | 4,356 | -1.6% | 1,167,200 | 2兆4299億 | -0.14% |
05/25 | 4,475 | 4,482 | 4,426 | 4,427 | -0.9% | 978,000 | 2兆4695億 | +1.63% |
05/24 | 4,498 | 4,509 | 4,462 | 4,467 | -0.8% | 819,300 | 2兆4918億 | +2.71% |
05/23 | 4,490 | 4,522 | 4,453 | 4,503 | +1.4% | 1,019,700 | 2兆5119億 | +3.8% |
05/20 | 4,474 | 4,494 | 4,435 | 4,441 | -0.98% | 1,392,100 | 2兆4773億 | +2.68% |
05/19 | 4,423 | 4,503 | 4,395 | 4,485 | -1.43% | 1,135,400 | 2兆5018億 | +3.89% |
05/18 | 4,486 | 4,555 | 4,478 | 4,550 | +2.32% | 1,412,700 | 2兆5381億 | +5.64% |
05/17 | 4,461 | 4,474 | 4,415 | 4,447 | +0.57% | 1,416,400 | 2兆4806億 | +3.56% |
05/16 | 4,350 | 4,504 | 4,350 | 4,422 | +2.46% | 1,095,400 | 2兆4667億 | +3.22% |
05/13 | 13:30 大塚製薬とアケビア社の腎性貧血治療薬におけるグローバルライセンス契約の終了について |
05/13 | 13:30 2022年12月期第1四半期決算短信〔IFRS〕(連結) |
05/13 | 4,400 | 4,420 | 4,250 | 4,316 | -1.82% | 1,840,300 | 2兆4076億 | +0.91% |
05/12 | 4,396 | 4,417 | 4,339 | 4,396 | -0.57% | 855,800 | 2兆4522億 | +2.83% |
05/11 | 4,406 | 4,450 | 4,401 | 4,421 | -0.45% | 895,000 | 2兆4661億 | +3.58% |
05/10 | 4,424 | 4,451 | 4,405 | 4,441 | +0.05% | 870,800 | 2兆4773億 | +4.22% |
05/09 | 4,495 | 4,506 | 4,419 | 4,439 | -1.86% | 936,900 | 2兆4762億 | +4.35% |
05/06 | 4,444 | 4,532 | 4,411 | 4,523 | +2.26% | 1,517,200 | 2兆5230億 | +6.5% |
05/02 | 4,351 | 4,430 | 4,303 | 4,423 | +1.38% | 1,225,600 | 2兆4673億 | +4.41% |
04/28 | 16:00 譲渡制限付株式報酬としての自己株式の処分の払込完了に関するお知らせ |
04/28 | 4,233 | 4,376 | 4,191 | 4,363 | +4% | 1,398,100 | 2兆4338億 | +3.17% |
04/27 | 4,239 | 4,239 | 4,165 | 4,195 | -1.99% | 1,497,700 | 2兆3401億 | -0.71% |
04/26 | 4,245 | 4,303 | 4,237 | 4,280 | +0.87% | 1,065,800 | 2兆3875億 | +1.23% |
04/25 | 4,217 | 4,254 | 4,195 | 4,243 | +0.24% | 742,900 | 2兆3668億 | +0.5% |
04/22 | 4,228 | 4,243 | 4,198 | 4,233 | -0.4% | 713,100 | 2兆3613億 | +0.33% |
04/21 | 4,215 | 4,282 | 4,173 | 4,250 | +1.8% | 895,500 | 2兆3708億 | +0.83% |
04/20 | 4,122 | 4,177 | 4,110 | 4,175 | +1.14% | 670,900 | 2兆3289億 | -0.74% |
04/19 | 4,134 | 4,151 | 4,108 | 4,128 | +0.29% | 553,700 | 2兆3027億 | -1.67% |
04/18 | 4,171 | 4,184 | 4,081 | 4,116 | -2.37% | 514,900 | 2兆2960億 | -1.77% |
04/15 | 4,203 | 4,236 | 4,174 | 4,216 | -0.57% | 475,400 | 2兆3518億 | +0.81% |
04/14 | 4,193 | 4,258 | 4,190 | 4,240 | +0.98% | 481,800 | 2兆3652億 | +1.61% |
04/13 | 4,126 | 4,213 | 4,125 | 4,199 | +0.53% | 856,900 | 2兆3423億 | +0.96% |
04/12 | 4,221 | 4,235 | 4,168 | 4,177 | -1.44% | 707,300 | 2兆3300億 | +0.8% |
04/11 | 4,230 | 4,247 | 4,202 | 4,238 | +0.02% | 810,600 | 2兆3641億 | +2.54% |
04/08 | 4,282 | 4,282 | 4,228 | 4,237 | -0.09% | 1,332,000 | 2兆3635億 | +2.81% |
04/07 | 4,180 | 4,248 | 4,159 | 4,241 | +1.41% | 934,800 | 2兆3657億 | +3.21% |
04/06 | 4,207 | 4,225 | 4,160 | 4,182 | -1.48% | 1,150,100 | 2兆3328億 | +2.15% |
04/05 | 4,300 | 4,303 | 4,210 | 4,245 | -0.84% | 1,024,100 | 2兆3680億 | +3.92% |
04/04 | 4,260 | 4,302 | 4,232 | 4,281 | +1.4% | 649,000 | 2兆3880億 | +5.11% |
04/01 | 4,211 | 4,225 | 4,149 | 4,222 | -0.24% | 858,500 | 2兆3551億 | +4.02% |
03/31 | 4,242 | 4,307 | 4,232 | 4,232 | -0.89% | 1,549,200 | 2兆3607億 | +4.57% |
03/31 | 8:30 腎性貧血治療薬「バダデュスタット」米国FDAから審査完了報告通知(CRL)を受理 |
03/30 | 16:30 譲渡制限付株式報酬としての自己株式の処分に関するお知らせ |
03/30 | 4,300 | 4,319 | 4,229 | 4,270 | -0.02% | 871,600 | 2兆3819億 | +5.77% |
03/29 | 4,241 | 4,272 | 4,219 | 4,271 | +0.9% | 865,800 | 2兆3825億 | +6.06% |
03/28 | 4,258 | 4,259 | 4,211 | 4,233 | -0.8% | 558,400 | 2兆3613億 | +5.35% |
03/25 | 4,268 | 4,272 | 4,208 | 4,267 | +0.47% | 797,600 | 2兆3802億 | +6.44% |
03/24 | 4,265 | 4,267 | 4,211 | 4,247 | -0.54% | 909,200 | 2兆3691億 | +6.18% |
03/23 | 4,200 | 4,284 | 4,185 | 4,270 | +2.94% | 1,137,000 | 2兆3819億 | +7.02% |
03/22 | 4,188 | 4,207 | 4,135 | 4,148 | -0.43% | 1,693,900 | 2兆3139億 | +4.27% |
03/18 | 4,174 | 4,194 | 4,105 | 4,166 | +0.99% | 1,852,500 | 2兆3239億 | +4.81% |
03/17 | 4,108 | 4,130 | 4,067 | 4,125 | +2.51% | 1,446,900 | 2兆3010億 | +3.88% |
03/16 | 4,030 | 4,060 | 4,023 | 4,024 | +1.28% | 925,700 | 2兆2447億 | +1.33% |
03/15 | 3,935 | 3,987 | 3,920 | 3,973 | +1.27% | 662,700 | 2兆2162億 | 0% |
03/14 | 3,965 | 4,023 | 3,916 | 3,923 | -0.15% | 972,400 | 2兆1883億 | -1.36% |
03/11 | 3,947 | 3,966 | 3,901 | 3,929 | -1.33% | 1,360,800 | 2兆1917億 | -1.31% |
03/10 | 3,897 | 3,997 | 3,879 | 3,982 | +2.58% | 1,425,100 | 2兆2213億 | -0.08% |
03/09 | 3,845 | 3,909 | 3,841 | 3,882 | +1.17% | 1,268,000 | 2兆1655億 | -2.49% |
03/08 | 3,851 | 3,887 | 3,831 | 3,837 | -1.39% | 885,200 | 2兆1404億 | -3.67% |
03/07 | 3,900 | 3,908 | 3,847 | 3,891 | -1.19% | 852,100 | 2兆1705億 | -2.43% |
03/04 | 3,971 | 3,982 | 3,923 | 3,938 | -0.18% | 759,900 | 2兆1967億 | -1.45% |
03/03 | 3,900 | 3,957 | 3,888 | 3,945 | +1.83% | 758,100 | 2兆2006億 | -1.47% |
03/02 | 3,868 | 3,891 | 3,852 | 3,874 | -1.63% | 944,900 | 2兆1610億 | -3.49% |
03/01 | 4,015 | 4,029 | 3,931 | 3,938 | -0.63% | 988,900 | 2兆1967億 | -2.21% |